Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy

British Journal of Cancer

Volumn 89, Issue 11, 2003, Pages 2045-2050

  Polee, M B ^a   Hop, W C J ^a   Kok, T C ^a   Eskens, F A L M ^a   Van Der Burg, M E L ^a   Splinter, T A W ^a   Siersema, P D ^a   Tilanus, H W ^a   Stoter, G ^a   Van Der Gaast, A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Chemotherapy; Cisplatin; Oesophagus; Prognosis; Survival

Indexed keywords

ALKALINE PHOSPHATASE; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; LACTATE DEHYDROGENASE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURVIVAL RATE; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS;

EID: 0346788918     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601364     Document Type: Article

References (28)

1. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1: 710-719
2. Andreyev HJN, Norman AR, Oates J, Cunningham D (1998) Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies. Eur J Cancer 34: 503-509
3. Blazeby JM, Farndon JR, Donovan J, Alderson D (2000) A prospective longitudinal study examining the quality of life in patients with oesophageal cancer. Cancer 88: 1781-1787
4. Blazeby JM, Williams MH, Brookes ST, Alderson D, Farndon JR (1995) Quality of life measurement in patients with oesophageal cancer. Gut 37: 505-508
5. Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jabob JH, Bedenne, Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33: 1216-1222
6. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE (2000) Outcome of patients receiving radiation for cancer of the oesophagus: results of the 1992-1994 patterns of care study. J Clin Oncol 18: 455-462
7. Cox DR (1972) Regression models and life-tables (with discussion). J R Stat Soc Ser B 34: 187-220
8. Enzinger PC, Ilson DH, Kelsen DP (1999) Chemotherapy in oesophageal cancer. Semin Oncol 26: 12-20
9. Ikeda G, Isaji S, Chandra B, Watanabe M, Kawarada Y (1999) Prognostic significance of biologic factors in squamous cell carcinoma of the oesophagus. Cancer 86: 1396-1405
10. Ilson DH, Forastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen PD (2000) A Phase II trial of paclitaxel and cisplatin in patients with advanced carcinoma of the oesophagus. Cancer J 6: 316-323
11. Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, De Groff J, Gonzalez G, Kelsen PD (1999) Phase II trial of weekly irinotecan plus cisplatin in advanced oesophageal cancer. J Clin Oncol 17: 3270-3275
12. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
13. Kato H, Tachimori Y, Watanabe H, Iizuka T (1993) Evaluation of the new (1987) TNM classification for thoracic oesophageal tumors. Int J Cancer 53: 220-223
14. Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA (1998) Chemotherapy followed by surgery compared with surgery alone for localized oesophageal cancer. N Engl J Med 339: 1979-1984
15. Knyrim K, Wagner HJ, Bethge N, Keymling M, Vakil N (1993) A controlled trial of an expansile metal stent for palliation of oesophageal obstruction due to inoperable cancer. N Engl J Med 329: 1302-1307
16. Kok TC, Splinter TAW, Van der Gaast A (1997) Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with adenocarcinoma of the oesophagus. Proc Am Soc Clin Oncol 16, 306: Abstract 1087
17. Kok TC, Van der Gaast A, Dees J, Eijkenboom WMH, Van Overhagen H, Stoter G, Tilanus HW, Splinter TAW (1996) Cisplatin and etoposide in oesophageal cancer: a phase II study. Br J Cancer 74: 980-984
18. Low DE, Pagliero KM (1992) Prospective randomized trial comparing brachytherapy and laser photoablation for palliation of oesophageal cancer. J Thorac Surg 104: 173-178
19. Mantel N (1966) Evaluation of survival data and two new rank order statistics in its consideration. Cancer Chemother Rep 50: 163-170
20. Millikan KW, Silverstein J, Hart V, Blair K, Bines S, Roberts J, Doolas A (1995) A 15-year review of oesophagectomy for carcinoma of the oesophagus and cardia. Arch Surg 130: 617-624
21. Muller JM, Erasmi H, Stelzner M, Zieren U, Pichlmaier H (1990) Surgical therapy of oesophageal carcinoma. Br J Surg 77: 845-857
22. Polee MB, Eskens FALM, van der Burg MEL, Splinter TAW, Siersema PD, Tilanus HW, Verweij J, Stoter G, Van der Gaast A (2002a) Phase 11 study of a biweekly schedule of cisplatin and paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 86: 667-669
23. Polee MB, Kok TC, Siersema PD, Tilanus HW, Splinter TAW, Stoter G, Van der Gaast A (2001) Phase II study of the combination cisplatin, etoposide, 5-fluorouracil and folinic acid in patients with advanced squamous cell carcinoma of the oesophagus. Anticancer Drugs 12: 513-517
24. Polee MB, Verweij J, Siersema PD, Tilanus HW, Splinter TAW, Stoter G, Van der Gaast A (2002b) Phase I study of a weekly schedule of a fixed dose of cisplatin and escalating doses of paclitaxel in patients with advanced oesophageal cancer. Eur J Cancer 38: 1495-1500
25. Shimada H, Takeda A, Nabeya Y, Okazumi SI, Matsubara H, Funami Y, Hayashi H, Gunji Y, Suzuki T, Ochiai T (2000) Clinical significance of serum vascular endothelial growth factor in oesophageal squamous cell carcinoma. Cancer 92: 663-669
26. Siersema PD, Dees J, van Blankenstein M (1998) Palliation of malignant dysphagia from oesophageal cancer. Scand J Gastroenterol 33(Suppl 225): 75-84
27. Van der Gaast A, Kok TC, Kerkhofs L, Siersema PD, Tilanus HW, Splinter TAW (1999) Phase I study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced oesophageal cancer. Br J Cancer 80: 1052-1057
28. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment, WHO Offset Publ., No. 4 Geneva: World Health Organization